Abstract 5821: DXC008, a novel STEAP1 antibody-tubulysin analog conjugate with a function linker, demonstrates a potential to broaden therapeutic opportunities for prostate tumors

Abstract

Abstract Six-transmembrane epithelial antigen of the prostate 1 (STEAP1), is a cell surface protein frequently expressed in prostate cancer, with limited expression in non-prostate tissues. A Steap1 antibody called Vandortuzumab conjugated with MMAE (DSTP3086S) was in the clinical phase I trial for treating STEAP1-expressing metastatic castration-resistant prostate cancer and showed acceptable safety at 2.4 mg/kg once every 3 weeks. However, many patients are nonresponsive to DSTP3086S due to low target expression levels and common treatment-related AEs which were caused by MMAE payloads. DXC008 was generated through screening the therapeutical index in vitro of conjugates of an anti-Steap1 antibody with varieties of payloads of tubulysin B analogs through function peptide spacer linkers. The generated DXC008 exhibited not only good affinity for Steap1 but also moderate affinity for Prostate-specific membrane antigen (PSMA) which is as well specifically overexpressed in most prostate cancer with limited expression in normal tissue. DXC008 demonstrated couple tens to a hundred of picomolar concentration (pM) of potency against several prostate tumor cells and over 60% internalization rate within 90 min in vitro. And in vivo it showed very good durable antitumor response as low dose as 1 mg/kg one injection in both high and moderate of both Steap1 and PSMA expression xenograft models. Pharmacokinetic profiles of DXC008 were favorable and the safety of Maximal Tolerable Dose (MTD) was over 120 mg/kg in single injection in mice. DXC008 has been forward to NHP toxicity study and it has potential to be a good STEAP1/PSMA-targeting ADC with a wide therapeutic window for prostate cancers. Citation Format: Qingliang Yang, Yuanyuan Huang, Junxiang Jia, Huihui Guo, Lingli Zhang, You Zhou, Zhicang Ye, Hangbo Ye, Yifang Xu, WenJun Li, Zhiyu Zhao, Lingyao Zhao, Lu Bai, Jun Zheng, Robert Y. Zhao. DXC008, a novel STEAP1 antibody-tubulysin analog conjugate with a function linker, demonstrates a potential to broaden therapeutic opportunities for prostate tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5821.